CAI
Caris Life Sciences, Inc.
$32.35
+1.25
(+4.00%)
Mkt Cap
9.17B
Volume
2,231,900
52W Range
14.19-33.13
Sector
Healthcare
Beta
0.68
EPS (TTM)
0.37 USD
P/E Ratio
87.23
Revenue (TTM)
989.61M USD
Rev Growth (5Y)
+22.5%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$7.73
Overvalued
strong signal
319.8% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 812.03M | 412.26M | 306.13M | 258.49M | 294.01M | 416.54M | 432.10M | 348.39M | 294.35M | 249.67M | 227.59M | 212.41M |
| Net Income | (537.96M) | (281.89M) | (341.42M) | (320.83M) | 27.73M | 31.01M | 78.60M | 72.06M | 6.00M | 26.84M | 60.27M | 63.93M |
| EPS | -1.91 | -2.70 | -1.82 | -1.57 | 1.55 | 1.72 | 3.97 | 3.74 | 0.31 | 1.29 | 2.91 | 2.89 |
| Free Cash Flow | 66.89M | (253.64M) | (298.42M) | (327.96M) | 57.57M | (65.14M) | (633.07M) | (346.98M) | (121.99M) | (242.04M) | (167.62M) | (188.02M) |
| FCF / Share | 0.24 | -1.00 | -1.17 | -1.29 | 3.21 | -3.62 | -31.94 | -18.02 | -6.31 | -11.65 | -8.09 | -8.49 |
| Operating CF | 83.16M | (245.20M) | (276.10M) | (285.71M) | 277.02M | 254.00M | 179.77M | 155.19M | 129.26M | 147.37M | 139.69M | 124.19M |
| Total Assets | 1.13B | 343.73M | 412.90M | 717.42M | 2.61B | 2.90B | 3.01B | 2.43B | 2.06B | 1.99B | 1.80B | 1.68B |
| Total Debt | 378.99M | 424.26M | 217.27M | 270.87M | 1.75B | 2.10B | 2.16B | 1.70B | 1.48B | 1.43B | 1.26B | 1.13B |
| Cash & Equiv | 797.80M | 63.95M | 56.40M | 107.19M | 53.55M | 46.46M | 45.31M | 35.42M | 46.13M | 52.55M | 53.82M | 45.74M |
| Book Value | 577.31M | (2.50B) | (2.14B) | (1.70B) | 702.24M | 693.24M | 701.13M | 563.85M | 457.50M | 460.34M | 442.12M | 414.53M |
| Return on Equity | -0.93 | N/A | N/A | N/A | 0.04 | 0.04 | 0.11 | 0.13 | 0.01 | 0.06 | 0.14 | 0.15 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263.71M | 216.17M | 292.89M | 216.83M | 181.40M | 120.92M | 100.05M | 80.68M | 100.83M | 85.69M | 80.80M | 64.32M |
| Net Income | (637,000) | (510,000) | 81.96M | 24.32M | (71.79M) | (102.58M) | (66.19M) | (111.03M) | 51.16M | 37.94M | 35.74M | 14.25M |
| EPS | -0.00 | -0.00 | 0.29 | 0.09 | -1.93 | -0.40 | -0.35 | -0.53 | 2.95 | 2.07 | 2.07 | 0.80 |
| Free Cash Flow | 28.94M | 22.53M | 39.69M | 55.33M | 5.90M | (34.03M) | (65.51M) | (75.66M) | (447.56M) | (18.80M) | (95.86M) | (91.42M) |
| FCF / Share | 0.10 | 0.08 | 0.14 | 0.20 | 0.02 | -0.13 | -0.26 | -0.30 | -25.82 | -1.09 | -5.55 | -5.16 |
| Operating CF | 61.35M | 32.88M | 44.78M | 62.42M | 7.29M | (31.34M) | (62.93M) | (73.92M) | 97.61M | 86.28M | 75.79M | 78.81M |
| Total Assets | 1.23B | 1.16B | 1.13B | 984.57M | 955.06M | 291.58M | N/A | 0 | 3.27B | 2.96B | 2.68B | 2.61B |
| Total Debt | 452.40M | 430.96M | 378.99M | 426.74M | 418.98M | 419.83M | N/A | 0 | 2.26B | 1.82B | 1.83B | 1.75B |
| Cash & Equiv | 690.91M | 821.15M | 797.80M | 753.22M | 718.93M | 31.20M | N/A | 121.59M | 47.03M | 38.81M | 47.91M | 53.55M |
| Book Value | 591.73M | 593.49M | 577.31M | 478.36M | 452.90M | (2.60B) | N/A | (19.67M) | 800.72M | 756.26M | 726.21M | 702.24M |
| Return on Equity | -0.00 | -0.00 | 0.14 | 0.05 | -0.16 | N/A | N/A | N/A | 0.06 | 0.05 | 0.05 | 0.02 |
CAI News
Caris Life Sciences, Inc. $CAI Shares Newly Bought by City Center Advisors LLC
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Caris Life Sciences: Diagnostics Growth With Room To Run
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript